Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)
AssigneeApceth GmbH & Co. KG
InventorsChristine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
Life of this patent
Estimating the term…
Abstract
Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (AAT) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
Claims25
A method for treating a subject having a medical conditions associated with inflammation and/or an unwanted immune response without an alpha1-antitrypsin (AAT) deficiency, wherein the method comprises administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells comprise an exogenous nucleic acid comprising (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
(canceled)
(canceled)
Dependencies are inferred from the claim text.